GENENTA SCIENCE SPA - ADR (GNTA) Stock Price, Forecast & Analysis
USA - NASDAQ:GNTA - US36870W1009 - ADR
GNTA Key Statistics, Chart & Performance
The current stock price of GNTA is 2.57 USD. In the past month the price decreased by -22.12%. In the past year, price decreased by -52.84%.
GNTA Latest News, Press Relases and Analysis
GNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About GNTA
Company Profile
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Company Info
GENENTA SCIENCE SPA - ADR
Via Olgettina 58
Milan MILANO IT
Employees: 13
GENENTA SCIENCE SPA - ADR / GNTA FAQ
Can you describe the business of GENENTA SCIENCE SPA - ADR?
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
What is the stock price of GENENTA SCIENCE SPA - ADR today?
The current stock price of GNTA is 2.57 USD. The price decreased by -10.45% in the last trading session.
What is the dividend status of GENENTA SCIENCE SPA - ADR?
GNTA does not pay a dividend.
How is the ChartMill rating for GENENTA SCIENCE SPA - ADR?
GNTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for GNTA stock?
GENENTA SCIENCE SPA - ADR (GNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
Would investing in GENENTA SCIENCE SPA - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNTA.
GNTA Technical Analysis
GNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GNTA. While GNTA has a great health rating, there are worries on its profitability.
GNTA Financial Highlights
Over the last trailing twelve months GNTA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 23.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.12% | ||
| ROE | -71.32% | ||
| Debt/Equity | 0 |
GNTA Forecast & Estimates
8 analysts have analysed GNTA and the average price target is 21.42 USD. This implies a price increase of 733.46% is expected in the next year compared to the current price of 2.57.